How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

632 results for

Wart Immune Therapy

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

441. We are human beings before we are doctors

the medical profession itself. A fact that should shock us out of our judgmental slumbers and wake us up to ask: What is really going on? Anxiety and depression are equally prevalent in the medical profession as in the general population and more worryingly, addiction and suicide rates are actually higher than the general population. So there is no doubt that medical professionals are not immune to mental illness — indeed, the opposite is true — for it seems that a medical degree is, in fact, hazardous (...) to one’s mental health; hardly an advertisement for the profession! It is hypocritical to talk about having compassion for patients who have mental illness when we still hold such stigmatizing views of it within the medical profession. It’s as if we think it’s OK for the group of human beings we call “patients” to get it, but once we cross the medical threshold we enter a culture where such conditions are not permitted, nor admitted to. Why is this? Do we believe that a medical degree should render us

2016 KevinMD blog

442. Overcoming obstacles to HPV vaccination

that introduction of the quadrivalent vaccine in 9 countries (including the U.S.) was associated with a 90% reduction in infections from the targeted genotypes and similar reductions in genital warts and high-grade cervical abnormalities. Women who receive HPV vaccine are at considerably lower risk for undergoing colposcopy and associated invasive diagnostic or therapeutic procedures. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) recommends that all boys (...) Overcoming obstacles to HPV vaccination The AFP Community Blog: Overcoming obstacles to HPV vaccination | Monday, August 22, 2016 - Kenny Lin, MD, MPH Human papillomavirus (HPV) vaccines, which prevent infection with HPV genotypes that cause cervical, anal, vaginal, and penile cancers, are hardly new. The and HPV vaccines were reviewed in AFP in 2007 and 2010, respectively, and a vaccine was approved by the U.S. Food and Drug Administration in 2014. Although long-term studies , a recent found

2016 The AFP Community Blog

443. HIV Course

From Related Chapters II. Background: Natural History of HIV Disease Total duration from initial to No treatment: 10 years Early therapy: May approach normal Active immune response after infection: 2.1 months Primary infection usually asymptomatic in 30-50% Initial infection with single Evolves into 15-20 distinct viral variants gains access to CD4 cells via sequential binding CD4 receptor via sequential binding with CD4 receptor in combination with CCR5 or CXCR4 co-receptors Over time: CD4 cell (...) received no therapy Course over following 18-24 months Risk of occult infection or death: <5% Slow decline in s (40 to 80 cells/year) VI. Staging: Intermediate Disease (CD4 Count 200 - 500 cells) HIV related disorders Pronounced , Recurrent Infection Recurrent Infection Pruritic Recurrent s Anogenital ulcers or warts Complications Atypical in this stage Management therapy is continued from prior stages Course (Untreated) over following 18-24 months Risk of occult infection or death: 20-30% Treatment

2015 FP Notebook

444. Cervical Cancer

class Uncircumcised male partner (unconfirmed) B-Carotene deficiency V. Pathophysiology Cervical Cancer is a HPV is found in all but 0.3% of Cervical Cancers HPV is common (affects 50% of U.S. adults 20-25 years old) Immune system clears HPV in 6 months for 50% and 2 years for 90% of women (HPV) High risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 Types 16 (especially) and 18 account for 70% of Cervical Cancers Low risk types (6 and 11) cause anogenital warts and are not typically (...) ) Prostitute: 4 fold increased risk Early age of first intercourse under age 18 years (RR >2) Male Partner with history of multiple partners use confers 1.5-3 fold increased risk (squamous cell Cervical Cancer) Immunosuppression Immunosuppressive drugs Previous abnormal or cervical biopsy most common abnormality before or cancer Lack of previous (50% of cancer patients) No in last 5 years (10% of cancer patients) History of (including HPV) Long term use >5 years (2 fold increased risk) Lower socioeconomic

2015 FP Notebook

445. Human Papilloma Virus Vaccine

) A vaccine used to prevent genital warts, cervical cancer, vulvar cancer, and vaginal cancer caused by certain types of human papillomavirus (HPV). It is also used to prevent lesions that are caused by those viruses and that can lead to cervical, vulvar, or vaginal cancer. Definition (NCI) A recombinant vaccine of different types of HPV proteins which are well-conserved within types with a significant inter-type variation. Concepts Immunologic Factor ( T129 ) , Pharmacologic Substance ( T121 ) , Amino (...) Acid, Peptide, or Protein ( T116 ) MSH SnomedCT 424519000 , 423929007 HL7 62 English HPV Vaccines , Human Papilloma Virus Vaccines , Human Papillomavirus Vaccines , Papillomavirus Vaccines, Human , Vaccines, Human Papillomavirus , human papillomavirus vaccine , Human papillomavirus vaccine (product) , Human papillomavirus vaccine , Human papillomavirus vaccine (substance) , HPV vaccine , human papilloma virus vaccine (medication) , human papilloma virus vaccine , HPV , Recombinant Human Papilloma

2015 FP Notebook

446. Imiquimod

information. Ontology: imiquimod (C0165032) Definition (NCI_NCI-GLOSS) A drug used to treat early basal cell skin cancer and certain other skin conditions. It is being studied in the treatment of other types of cancer. Imiquimod is a type of biological response modifier. Definition (NCI) A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly (...) -amine , 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)- , imiquimod , 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline , IMQ , imiquimod (medication) , wart therapeutic agents imiquimod , imiquimod [Chemical/Ingredient] , IMIQUIMOD , Imiquimod , Imiquimod (product) , Imiquimod (substance) Spanish imiquimod (producto) , imiquimod (sustancia) , imiquimod Derived from the NIH UMLS ( ) Ontology: Aldara (C0718327) Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH English

2015 FP Notebook

447. Skin Infection

, Pyoderma , Fungal Dermatoses , Parasite infestation , Parasitic Infections of the Skin , Skin and Soft Tissue Infection , SSTI , Skin and Subcutaneous Tissue Infection and Infestation From Related Chapters II. Pathophysiology: Predisposing factors Decreased tissue perfusion oxygenation Peripheral fluid stasis and edema Increased risk Suppressed immune function III. Types: Bacterial Skin Infections (Pyoderma) ( or ), or Staphylococcal Scalded Skin Infection and IV. Types: Complicated Bacterial Skin (...) : and . can also affect the skin. Viral: , , and Fungal: and Parasitic: , , and Treatment of skin infections depends on the cause. Definition (MSHCZE) Nemoci kůže způsobené bakteriemi, plísněmi, parazity nebo viry. Definition (NCI) An inflammatory process affecting the skin, caused by bacteria, viruses, parasites, or fungi. Examples of bacterial infection include carbuncles, furuncles, impetigo, erysipelas, and abscesses. Examples of viral infection include shingles, warts, molluscum contagiosum

2015 FP Notebook

448. Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

, but not limited to HIV-1, HSV-2, Chlamydia trachomatis (CT), Trichomonas vaginalis (TV), Neisseria Protocol # D11-119 Version 2.0 April 13, 2012 10 gonorrhea (NG), Hepatitis B, high risk HPV sub types and or Syphilis), yeast vaginitis or bacterial vaginosis (BV); Current use of chronic immunosuppressants (for example daily steroids or daily non-steroidal anti-inflammatory drugs [NSAIDs]); Current presence of vulvar, anal and or vaginal genital warts; Current tobacco use of any amount; Other conditions (...) that, in the opinion of the investigator, would constitute contraindications to participation in the study or would compromise the ability to comply with study protocols, such as any major chronic illness including but not limited to cancer, serious autoimmune disease, metabolic disorders or a major psychiatric disorder (e.g., schizophrenia); and Current participation in any other drug or device study, or any study which, in the Contacts and Locations Go to Information from the National Library of Medicine

2012 Clinical Trials

449. SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma

University Hospital Collaborator: G&E Herbal Biotechnology Co., LTD Information provided by (Responsible Party): National Cheng-Kung University Hospital Study Details Study Description Go to Brief Summary: This pilot clinical study is to evaluate the efficacy & safety of SR-T100 gel (2.3% of SM in Solanum undatum plant extract) in patients with VIN(s) or EGW(s). Condition or disease Intervention/treatment Phase Vulvar Intraepithelial Neoplasia Genital Warts Drug: SR-T100 gel with 2.3% of SM in Solanum (...) by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Lesion reduction Drug: SR-T100 gel with 2.3% of SM in Solanum undatum plant extract Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning

2012 Clinical Trials

450. Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

: May 26, 2015 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Group 1 Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks) Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir (...) for each participant for each period based on participant self-report, staff estimates and PK testing results. Other Outcome Measures: Pharmacodynamics [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ] To characterize pharmacodynamic responses following oral and rectal exposure to antiretroviral drugs Mucosal Immunity [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ] To characterize changes in mucosal

2012 Clinical Trials

451. A Phase I Clinical Trial of an HPV Therapeutic Vaccine

studies have revealed that immune response to E6 is important in fighting HPV. We also know that injecting Candin has anti-HPV effect since it has been used to treat common warts which are caused by different types of HPV. The current standard treatment for HSIL is loop electrical excision procedure (LEEP). The immune system is the part of the body that fights infection and cancer. This research study will also examine the immune response to the vaccine and its effectiveness in regressing HSIL (...) of vaccinations or procedures ] Clinical response as defined by loop electrical excision procedure (LEEP); virological assessment to assess the clearance of HPV infection after vaccination; immunological assessments of T-Cells and circulating immune cells (regulated T-Cells and myeloid derived suppressor cells); and assessment of cervical immune cells. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk

2012 Clinical Trials

452. Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women

); intrauterine device (IUD); and sterilization (of participant, as defined in site SOPs) At screening and enrollment, agrees not to participate in other research studies involving drugs, medical devices, vaginal products, or vaccines for the duration of study participation -- Note: Tampons may be used for the duration of the trial. Exclusion Criteria: Per participant report at screening: Intends to become pregnant during study participation Plans to relocate away from the study site during study (...) and asymptomatic candidiasis — are offered treatment and may be enrolled after completing treatment and all symptoms have resolved. If treatment is completed and symptoms have resolved within 28 days of obtaining informed consent for screening, the participant may be enrolled. Genital warts requiring treatment also must be treated prior to enrollment. Genital warts requiring therapy are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance

2012 Clinical Trials

453. Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases

infections such as genital ulcerations, anogenital herpes, anogenital warts, cancroids or syphilitic lesions Use of illicit drugs Travel within the last 6 months to areas of the world where diarrheal illnesses are endemic History or signs of immunosuppression i) History of any immunosuppressant medication(s) within the last 6 months or history of opportunistic infection(s) in past 1 year ii) Signs of immunosuppression such as: Oral thrush Disseminated lymphadenopathy Contacts and Locations Go (...) : December 2012 Actual Study Completion Date : June 2013 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Study Participants Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT. Drug: Gut Microbial Transplantation Each participant received Gut Microbial Transplantation (GMT) as retention enema

2012 Clinical Trials

454. Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students

provides maximum protection if administered prior to sexual debut, HPV4 guidelines recommend administration to males and females ages 11 and 12, with catch-up vaccination up to age 26, for the prevention of cervical and anal cancers as well as for the prevention of genital warts.1,5-8 Although vaccination against HPV-related cancers is a significant breakthrough, uptake is low. The National Immunization Survey—Teen (NIS-teen) estimated that in 2013, HPV vaccination coverage for 13-17 year-old females (...) 16 and 18 causing roughly 70% of cervical cancers worldwide.1 Persistent HPV infection has also been linked to vaginal and vulvar cancer in women, penile cancer in men, as well as oral pharyngeal cancer, anal cancer, and genital warts in both sexes.2-4 There are two safe and effective vaccines which protect against HPV types 16 and 18 and one of the two vaccines (HPV4) also protects against two additional HPV types that account for 90% of the cases of genital warts.5 Because HPV vaccination

2012 Clinical Trials

455. Intradermal Trivalent Influenza Vaccine With Imiquimod

to compare the safety and immunogenicity between intradermal 2011/2012 TIV immunization with pretreatment of imiquimod cream and conventional full dose intramuscular 2011/2012 TIV immunization with pretreatment of aqueous cream as control. Condition or disease Intervention/treatment Phase Chronic Illness Biological: influenza vaccine Drug: Imiquimod Drug: Aqueous cream Not Applicable Detailed Description: References World Health Organization. Influenza A (H1N1) - update 95 [cited 2010 April 10 (...) months prior to vaccination in this study. Have known active human immunodeficiency virus (HIV) infection, acute hepatitis B or C infection, autoimmune hepatitis and related cirrhosis Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. Unwilling to refuse participation in another clinical study through the end of this study. History of progressive

2012 Clinical Trials

456. A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

will be allowed for individuals who are non immune to Hepatitis B but undergo vaccination.) Availability to return for all study visits, barring unforeseen circumstances Willing to abstain from RAI and practices involving insertion of anything in rectum (drug, enema, penis, or sex toy) for 72 hours before and 72 hours after each flexible sigmoidoscopy and study product exposure. Must agree to use study provided condoms for the duration of the study Must be in general good health Must agree not to participate (...) of more than 2 drinks per day for men, and more than 1 drink per day for women), frequent binge drinking or illicit drug use that includes any injection drugs, methamphetamines (crystal meth), heroin, or cocaine including crack cocaine, within the past 12 months Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications during the period of study participation: Heparin, including Lovenox® Warfarin Plavix® (clopidogrel bisulfate) Rectally

2012 Clinical Trials

457. V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

prior to injection Exclusion Criteria: Received a marketed HPV vaccine Prior abnormal Papanicolaou smear (PAP) or biopsy showing CIN Known history of positive test for HPV Known history of genital warts Received immune globulin or blood products within 6 months prior to first injection or plan to receive any through Month 7 of the study History of splenectomy, known immune disorders, or receiving immunosuppressives Immunocompromised or diagnosed as having human immunodeficiency virus (HIV) Contacts (...) and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT01544478 Sponsors and Collaborators Merck Sharp & Dohme Corp. Investigators Layout table for investigator information Study Director: Medical Director Merck Sharp & Dohme Corp. More Information Go to Publications

2012 Clinical Trials

458. Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult MC Programs in Zimbabwe

Last Update Posted : October 8, 2013 Sponsor: Ministry of Health and Child Welfare, Zimbabwe Information provided by (Responsible Party): Prof. Mufuta Tshimanga, Ministry of Health and Child Welfare, Zimbabwe Study Details Study Description Go to Brief Summary: The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe Condition or disease Intervention (...) Programs in Zimbabwe Study Start Date : October 2011 Actual Primary Completion Date : November 2011 Actual Study Completion Date : November 2011 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Experimental: PrePex™ device Adult male circumcision by the PrePex™ device Device: PrePex™ device PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia Outcome

2012 Clinical Trials

459. Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)

applied compound named diphenylcyclopropenone (DPCP) which has been shown to be effective in treating melanoma patients whose diseases have spread widely throughout the skin. DPCP works by having a patient's own immune system, which is usually used to fight infections, attack cancerous cells. This compound has commonly been used to treat other conditions such as warts and hair loss throughout the world for many years and is known to cause limited side effects. Altering a patient's own immune system (...) through topical treatments has also been shown to benefit patients with other cancers that have metastasized to skin such as breast cancer. In this study, the investigators will use DPCP to treat cutaneous metastases of various cancers including melanoma. Our overall intention is to get a better understanding of effective immune responses in the skin that may mediate metastatic cancer regression or cure. Condition or disease Intervention/treatment Phase Neoplasm Metastasis Melanoma Drug

2012 Clinical Trials

460. Acquired Epidermodysplasia Verruciformis Due to Multiple and Unusual HPV Infection Among Vertically-Infected, HIV-Positive Adolescents in Zimbabwe. Full Text available with Trip Pro

, together with genital lesion-associated HPV types 6, 16, and 52, (as well as ≥3 other genital lesion-associated HPV types). Despite immune reconstitution with combination antiretroviral therapy (cART), there was no improvement in EV-like lesions in any patient.EV is a disfiguring and potentially stigmatizing condition among this patient group and is difficult to treat; cART appears to have no impact on the progression of skin disease. Among adolescents with longstanding HIV-induced immunosuppression (...) affected sites in 4 HIV-infected adolescents with EV-like lesions in Harare. Biopsies were processed for histology and for human papillomavirus (HPV) typing.All patients had long-standing skin lesions that pre-dated the diagnosis of HIV by several years. The histology of skin biopsies from all patients was consistent with EV. In each biopsy, EV-associated β-HPV type 5 was identified (additionally, type 19 was found in 1 biopsy). Cutaneous wart-associated HPV types 1 and 2 were detected in all biopsies

2012 Clinical Infectious Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>